	US 11,981,924 B2
	Composition for culturing NK cells and method for culturing NK cells using same
Hee Jung An, Seoul (KR); Yeon Ho Choi, Seoul (KR); Eun Jin Lim, Seongnam-si (KR); Yong Wha Moon, Seongnam-si (KR); and Se Wha Kim, Seongnam-si (KR)
Assigned to SUNGKWANG MEDICAL FOUNDATION, Seoul (KR)
Filed by SUNGKWANG MEDICAL FOUNDATION, Seoul (KR)
Filed on Jul. 17, 2023, as Appl. No. 18/353,182.
Application 18/353,182 is a continuation of application No. 16/645,215, granted, now 11,746,327, previously published as PCT/KR2018/014294, filed on Nov. 20, 2018.
Claims priority of application No. 10-2017-0158577 (KR), filed on Nov. 24, 2017.
Prior Publication US 2023/0365932 A1, Nov. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 35/00 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01)

CPC C12N 5/0646 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01)]

2 Claims

1. A method of treating cancer, the method comprising administering an effective amount of NK cells prepared by a method of culturing natural killer cells (NK cells), wherein the method comprising culturing the NK cells in a composition for culturing NK cells, the composition comprising IL-15 in an amount of 5.0 ng/ml to 20 ng/ml, IL-18 in an amount of 0.25 ng/ml to 2500 ng/ml, IL-27 in an amount of 0.20 ng/ml to 2000 ng/ml, and insulin transferrin selenium (ITS).